

Appln. Serial No. 09/787,397
Amendment After Final Rejection Under 37 CFR 1.116
And Summary Of Telephonic Interview
Docket No. FJIN-107

Amendments to the Claims:

This listing of claims will replace all prior listings of claims in the application.
Please cancel Claims 13, 21, and 29, without prejudice or disclaimer, and amend Claims 14-20, 22, and 25.

1-13. (Canceled)

14. (Currently Amended) A method ~~for treating or preventing obesity~~ according to claim ~~[[13]]~~ 22 wherein said pharmaceutical composition is administered orally or parenterally.

15. (Currently Amended) A method ~~for treating or preventing obesity~~ according to claim ~~[[13]]~~ 22 wherein said pharmaceutical composition is in a form selected from the group consisting of compositions for injection, compositions for dripping, suppositories, nasal agents, sublingual agents and percutaneous absorption agents.

16. (Currently Amended) A method ~~for treating or preventing obesity~~ according to claim ~~[[13]]~~ 22 wherein said pharmaceutical composition further comprises pharmaceutically acceptable carriers, excipients, stabilizers, coloring matters, or surfactants.

17. (Currently Amended) A method ~~for treating or preventing obesity~~ according to claim ~~[[13]]~~ 22 wherein said pharmaceutical composition is a composition formulated for injection comprising a pharmacologically effective amount of stanniocalcin and at least one pharmaceutically acceptable excipient and/or activator.

Appln. Serial No. 09/787,397

Amendment After Final Rejection Under 37 CFR 1.116

And Summary Of Telephonic Interview

Docket No. FJIN-107

18. (Currently Amended) A method for ~~treating or preventing obesity~~ according to claim 17 wherein said excipient and/or activator comprise amino acids, human serum albumin, sugars, and/or cellulose derivatives.

19. (Currently Amended) A method for ~~treating or preventing obesity~~ according to claim ~~[[13]]~~ 22 wherein said pharmaceutical composition is administered at a daily dose of 10 µg to 10 mg/kg body weight.

20. (Currently Amended) A method for ~~treating or preventing obesity~~ according to claim ~~[[13]]~~ 22 wherein said pharmaceutical composition is administered intravenously.

21. (Canceled)

22. (Currently Amended) A method for inhibiting adipocyte activity which comprises administering to ~~humans~~ a human in need of adipocyte inhibiting activity a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

23. (Previously Presented) A method for inhibiting adipocyte activity according to Claim 22, wherein adipocyte differentiation is inhibited.

24. (Previously Presented) A method for inhibiting adipocyte activity according to Claim 22, wherein adipocyte maturation is inhibited.

Appln. Serial No. 09/787,397
Amendment After Final Rejection Under 37 CFR 1.116
And Summary Of Telephonic Interview
Docket No. FJIN-107

25. (Currently Amended) A method for inhibiting adipocyte activity which comprises administering to ~~animals~~ an animal in need of adipocyte inhibiting activity a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

26. (Previously Presented) A method for inhibiting adipocyte activity according to Claim 25, wherein adipocyte differentiation is inhibited.

27. (Previously Presented) A method for inhibiting adipocyte activity according to Claim 25, wherein adipocyte maturation is inhibited.

28. (Previously Presented) A method for inhibiting adipogenesis in adipocytes comprising administering a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

29. (Canceled)